BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 30146721)

  • 1. Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy.
    Paget SP; Swinney CM; Burton KLO; Bau K; O'Flaherty SJ
    Dev Med Child Neurol; 2018 Nov; 60(11):1172-1177. PubMed ID: 30146721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of cerebral palsy and likelihood of adverse events after botulinum toxin A injections.
    Swinney CM; Bau K; Burton KLO; O'Flaherty SJ; Bear NL; Paget SP
    Dev Med Child Neurol; 2018 May; 60(5):498-504. PubMed ID: 29451702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.
    Naidu K; Smith K; Sheedy M; Adair B; Yu X; Graham HK
    Dev Med Child Neurol; 2010 Feb; 52(2):139-44. PubMed ID: 20412252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Questionnaire about the adverse events and side effects following botulinum toxin A treatment in patients with cerebral palsy.
    Blaszczyk I; Foumani NP; Ljungberg C; Wiberg M
    Toxins (Basel); 2015 Nov; 7(11):4645-54. PubMed ID: 26561833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medial gastrocnemius volume and echo-intensity after botulinum neurotoxin A interventions in children with spastic cerebral palsy.
    Schless SH; Cenni F; Bar-On L; Hanssen B; Kalkman B; O'brien T; Aertbeliën E; Van Campenhout A; Molenaers G; Desloovere K
    Dev Med Child Neurol; 2019 Jul; 61(7):783-790. PubMed ID: 30320442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of a Propofol and Ketamine Based Procedural Sedation Protocol in Children with Cerebral Palsy Undergoing Botulinum Toxin A Injections.
    Louer R; McKinney RC; Abu-Sultaneh S; Lutfi R; Abulebda K
    PM R; 2019 Dec; 11(12):1320-1325. PubMed ID: 30761757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk-stratified approach toward safely resuming OnabotulinumtoxinA injections based on dosing and ambulatory status in pediatric patients with cerebral palsy during the Coronavirus pandemic of 2019 (COVID-19).
    McLaughlin MJ; Fisher MT; Vadivelu S; Ramsey J; Ratnasingam D; McGhee E; Hartman K
    J Pediatr Rehabil Med; 2020; 13(3):273-279. PubMed ID: 33252098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Muscle volume alterations after first botulinum neurotoxin A treatment in children with cerebral palsy: a 6-month prospective cohort study.
    Alexander C; Elliott C; Valentine J; Stannage K; Bear N; Donnelly CJ; Shipman P; Reid S
    Dev Med Child Neurol; 2018 Nov; 60(11):1165-1171. PubMed ID: 30151852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin A for nonambulatory children with cerebral palsy: a double blind randomized controlled trial.
    Copeland L; Edwards P; Thorley M; Donaghey S; Gascoigne-Pees L; Kentish M; Cert G; Lindsley J; McLennan K; Sakzewski L; Boyd RN
    J Pediatr; 2014 Jul; 165(1):140-146.e4. PubMed ID: 24630348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Responsiveness of the ACTIVLIM-CP questionnaire: measuring global activity performance in children with cerebral palsy.
    Paradis J; Arnould C; Thonnard JL; Houx L; Pons-Becmeur C; Renders A; Brochard S; Bleyenheuft Y
    Dev Med Child Neurol; 2018 Nov; 60(11):1178-1185. PubMed ID: 29869417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative effects of submandibular botulinum neurotoxin A injections on oral motor function in children with drooling due to central nervous system disorders.
    van Hulst K; Kouwenberg CV; Jongerius PH; Feuth T; van den Hoogen FJ; Geurts AC; Erasmus CE
    Dev Med Child Neurol; 2017 May; 59(5):531-537. PubMed ID: 27901263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of botulinum toxin A in children and adolescents with cerebral palsy in a pragmatic setting.
    Papavasiliou AS; Nikaina I; Foska K; Bouros P; Mitsou G; Filiopoulos C
    Toxins (Basel); 2013 Mar; 5(3):524-36. PubMed ID: 23482250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Submandibular duct ligation after botulinum neurotoxin A treatment of drooling in children with cerebral palsy.
    Bekkers S; Pruijn IMJ; Van Hulst K; Delsing CP; Erasmus CE; Scheffer ART; Van Den Hoogen FJA
    Dev Med Child Neurol; 2020 Jul; 62(7):861-867. PubMed ID: 32149393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of salivary gland botulinum Toxin-A on drooling and respiratory morbidity in children with neurological dysfunction.
    Gubbay A; Marie Blackmore A
    Int J Pediatr Otorhinolaryngol; 2019 Sep; 124():124-128. PubMed ID: 31185343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining strength training and botulinum neurotoxin intervention in children with cerebral palsy: the impact on muscle morphology and strength.
    Williams SA; Elliott C; Valentine J; Gubbay A; Shipman P; Reid S
    Disabil Rehabil; 2013 Apr; 35(7):596-605. PubMed ID: 22928803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8-year retrospective study.
    Li J; He L; Tang H; Peng T; Long Y; Zeng P; Huang Y; Chen Z; Han M; Xu K
    Dev Med Child Neurol; 2023 Jan; 65(1):86-93. PubMed ID: 35674175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy: a pharmaco-epidemiological study in VigiBase.
    Montastruc J; Marque P; Moulis F; Bourg V; Lambert V; Durrieu G; Montastruc JL; Montastruc F
    Dev Med Child Neurol; 2017 Mar; 59(3):329-334. PubMed ID: 27682175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events after different forms of botulinum neurotoxin A injections in children with cerebral palsy: An 8-year retrospective study.
    Dev Med Child Neurol; 2024 Jul; 66(7):e81. PubMed ID: 38773794
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of botulinum toxin A in children with cerebral palsy in Gross Motor Function Classification System levels IV and V: a systematic review.
    Pin TW; Elmasry J; Lewis J
    Dev Med Child Neurol; 2013 Apr; 55(4):304-13. PubMed ID: 23095013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following botulinum toxin type A treatment in children with cerebral palsy.
    Langdon K; Blair E; Davidson SA; Valentine J
    Dev Med Child Neurol; 2010 Oct; 52(10):972-3; author reply 974. PubMed ID: 20561011
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.